InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,627.28
(
0.21%
)
US TECH 100
19,824.40
(
0.16%
)
Dow Jones
40,166.03
(
0.41%
)
Brent Oil
84.20
(
-0.47%
)
Bitcoin
63,353.28
(
4.24%
)
Post# of 252599
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120045
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 214659

Friday, 10/27/2017 9:23:49 AM

Friday, October 27, 2017 9:23:49 AM

Post# of 252599
3Q17 Mavyret sales—(partial quarter)—close to $100M, according to ABBV's 3Q17 CC.

"Close to $100M" is not bad considering that Mavyret was approved by the FDA on 8/3/17, and the commercial launches in the EU and Japan have not really begun yet.

The $250M bogey I set for (calendar) 4Q17 looks very doable (#msg-135663031, #msg-135730739).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up